CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Sodium Sulfite, RE		*USP36–NF31*	1196	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Anhydrous	AGENTS/*Reagent Specifications*							[7753-83-7] to: [7757-83-7]
ONDANSETRON ORAL SOLUTION	*Assay*	*USP36–NF31*	4586	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change (293.36/329.82) $100(C/V)(r_U / r_S)$ to: (293.36 / 329.83)$100(C / V)(r_U / r_S)$ AND Line 8 of *Procedure*: Change 329.82 to: 329.83
BUTYLPARABEN	IMPURITIES/*Related Substances*/*Chromatographic system*	*Second Supplement to USP36–NF31*	6551	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	After the *Column* section: Add *Column temperature*: 35°
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATION	STABILITY CRITERIA AND BEYOND-USE DATING/*General*	*Revision Bulletin (Official January 01, 2014)*	Online	28-Mar-2014	1-Apr-2014	*Second Supplement to USP37–NF32*	*Second Supplement to USP37–NF32*	Line 7 of Paragraph 1: Change (see the *General Notices*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
S	*Guidelines for Assigning Beyond-Use Dates*							*and Requirements, Preservation, Packaging, Storage, and Labeling*) to: (see <659>)
MELPHALAN TABLETS	*Dissolution <711>*	*USP36–NF31*	4232	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change Prepare a filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1 500:500:2:2:0.4). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). to: Transfer 2 grams of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ammonium acetate, 2 mL of glacial acetic acid, and 0.4 mL of triethylamine to a suitable flask containing 1500 mL of water and 500 mL of acetonitrile. Stir until all solids are dissolved and well mixed, then filter and degas.
THIMEROSAL	IMPURITIES/*Mercury Ions*	*USP36–NF31*	5368	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 19 of *Analysis*: C_S = concentration of mercuric chloride in the *Standard solution* (mg/mL) to: C_S = concentration of mercuric chloride in *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ONDANSETRON INJECTION	*Assay*	*Second Supplement to USP36–NF31*	Online	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	*B* (mg/mL) Line 7 of *Procedure*: Change (293.36 / 329.82)(25*C* / *V*)(r_U / r_S) to: (293.36 / 329.83)(25*C* / *V*)(r_U / r_S) AND Line 8 of *Procedure*: Change 329.82 to: 329.83
MAGNESIUM ALUMINUM SILICATE	IMPURITIES/*Arsenic, Method I <211>*	*USP36–NF31*	2073	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Standard preparation*: Change Prepare as directed in the chapter. to: Transfer 5.0 mL (5 ?g of arsenic) of the *Standard Arsenic Solution* to a 25-mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Delete: *Control preparation*: Transfer 5.0 mL (5 ?g of As) of the *Standard preparation* to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Line 1 of *Acceptance criteria*: Change the absorbance due to any red color from the *Test preparation* does not exceed that produced by the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Control preparation. to: the absorbance due to any red color from the *Test preparation* does not exceed that produced by the *Standard preparation*.
SODIUM ACETATE	IM PUR ITIES/*Inorganic Impuri ties*/*Potassium*	*USP36–NF31*	5147	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CARBIDOPA AND LEVODOPA ORALLY DISINTEGRATING TABLETS	ASSAY	*Second Supplement to USP36–NF31*	6580	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Change To 5 mL of *Sample solution* add to: To the *Sample solution* add Line 2 of *Procedure*: Change Inject the *Sample solution* within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light.
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH/ *Molybdenum, Method 1*	*Second Supplement to USP36–NF31*	6372	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Standard solutions*: Change 2.0 to: 5.0
GLYCERYL	IDENTIFICATIO	*USP36–NF31*	2033	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second*	Line 19 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TRISTEARATE	N/*Fatty Acid Composition*						*Supplement to USP37–NF32*	*Analysis*: Change Result = [(F_{MC} × P_{FA1} × A_{MC})/(P_{MC} × A_{FA1})] × 100 to: Result = (F_{MC} × P_{FA1} × A_{MC})/(P_{MC} × A_{FA1})
DICLOFENAC SODIUM DELAYED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*Procedure*	*USP36–NF31*	3221	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 22 of *Analysis*: Change r_S = peak response for each impurity from the *Standard solution* to: r_S = peak response of diclofenac related compound A from the *Standard solution*
TIZANIDINE TABLETS	IMPUR	*USP36–NF31*	5408	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to*	Line 9 of *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities/Procedure*						*USP37–NF32*	*solution*: Change 45-µm or finer pore size to: 0.45-µm or finer pore size
OXALIPLATIN INJECTION	IM PURITIES/*Limit of Oxalic Acid*	*First Supplement to USP36–NF31*	6033	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Analysis*: Change Calculate the percentage of each impurity to: Calculate the percentage of oxalic acid
WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	ST REN GTH/ *Molybdenum, Method 1*	*Second Supplement to USP36–NF31*	6479	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Standard solutions*: Change 2.0 to: 5.0
CEFTAZIDIME FOR INJECTION	*Assay*	*USP36–NF31*	2887	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 6 of *Procedure*: Change 250,000[*C*/*W* (100 ? *m* ? *s*)]() to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								25,000{*C*/[*W* (100 ? *m* ? *s*)]}(r_U / r_S)
RIBOFLAVIN 5 ?-PHOSPHATE SODIUM	IMPURITIES/*Free Riboflavin and Riboflavin Diphosphates*	*USP36–NF31*	5037	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Emission wavelength*: Change 530 nm to: 530 nm (monochromator-based detector) or 470 nm (filtered-type detector)
CYCLOMETHICONE	ASSAY/*Procedure*/*System suitability*	*First Supplement to USP36–NF31*	5909	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Suitability requirements*: Change *Relative standard deviation*: NMT 2.0% for cyclomethicone 4, cyclomethicone 5, and cyclomethicone 6, *Standard solution A*, *Standard solution B*, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution C to: *Relative standard deviation*: NMT 2.0% for cyclomethicone 4, *Standard solution A*; NMT 2.0% for cyclomethicone 5, *Standard solution B*; NMT 2.0% for cyclomethicone 6, *Standard solution C*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION	STRENGTH/*Chromium*	*Second Supplement to USP36–NF31*	6399	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 13 of *Analysis*: Change *C* = concentration of chromium in the *Standard solution* (µg/mL) to: *C* = concentration of chromium in the *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(µg/mL)
ANAGRELIDE HYDROCHLORIDE	ASSAY/*Procedure*/*Chromatographic system*/*System suitability*	*USP36–NF31*	2500	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Suitability requirements*: Change *Column efficiency*: NMT to: *Column efficiency*: NLT
DILTIAZEM HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*USP36–NF31*	3258	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 21 of *Analysis*: Change r_S = response of each impurity peak from the *Standard solution* to: r_S = peak response of desacetyl diltiazem from the *Standard solution*
VANCOMYCIN HYDROCHLORIDE	SPECIFIC TESTS/*Composition of Vancomycin*	*USP36–NF31*	5543	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 28 of *Analysis*: Change Result = $[(r_I/(D \times r_B) + r_A)] \times 100$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Result = $\{r_I/[(D \times r_B) + r_A]\} \times 100$
CONTAINERS GLASS-EVALUATION OF INNER SURFACE DURABILITY	EVALUATION OF THE INNER SURFACE DUR ABILITY/*Aggressive Screening Conditions*	*Second Supplement to USP36–NF31*	6221	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Row 1 of Column 3 of *Table 4*: Change 3% Citric Acid pH 8.0 to: 3% Sodium Citrate pH 8.0
ISOPROPYL ALCOHOL	ASSAY/ *Procedure*	*Second Supplement to USP36–NF31*	6638	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 17 of *Chromatographic system*: Change *Linear velocity*: 35 cm/s to: *Flow rate*: 2.3 mL/min AND Row 2 of Column 1 of *Table 2*: Change Diethyl ether to: Ethyl ether
CLARITHROM	ASSAY/	*USP36–NF31*	3016	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
YCIN	*Procedure/System suitability*						*Supplement to USP37–NF32*	*Samples*: Change *Standard solution 2* and *Standard solution 4* to: *Standard solution 1*, *Standard solution 2*, and *Standard solution 4* AND Line 13 of *Suitability requirements*: Change *Relative standard deviation*: NMT 1.5%, *Standard solution 2* to: *Relative standard deviation*: NMT 1.5%, *Standard solution 1*
RISPERIDONE TABLETS	*Dissolution <711>*	*USP36–NF31*	5065	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to*	Line 4 of *Chromatographi*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							USP37–NF32	*c system*: Change Chromatograph the *Standard solution* and the *Test solution* as directed for *Procedure*: to: Chromatograph the *Standard solution* as directed for *Procedure*:
ATOMOXETINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 2*	*First Supplement to USP36–NF31*	5947	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 5 of *System suitability solution*: Change dissolving the Reference Standards in ethanol, to: dissolving the Reference Standards in absolute alcohol, AND Line 2 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample solution: Change dissolving it in ethanol, to: dissolving it in absolute alcohol,
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION	CONTAMINANTS	*Second Supplement to USP36–NF31*	6399	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Add the test: *Absence of Specified Microorganisms* <2022>: Meet the requirements of the tests for the absence of *Salmonella species*, *Escherichia coli*, and *Staphylococcus aureus*
CANDESARTAN CILEXETIL	ASSAY/ *Procedure*	*USP36–NF31*	2774	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Analysis*: Change Titrate with 8 mL of 0.1 N to: Titrate with 0.1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FENTANYL	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP36–NF31*	3554	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	N Footnote f of Table 2: Change *N*-Phenyl-*N*-[1-(2-phenylethyl)-4-piperidinyl] acetanilide hydrochloride, or acetyl fentanyl. to: *N*-(1-Phenethylpiperidin-4-yl)-*N*-phenylacetamide.
VANCOMYCIN HYDROCHLORIDE FOR INJECTION	SPECIFIC TESTS/*Content of Vancomycin*	*USP36–NF31*	5546	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 27 of *Analysis*: Change Result = $[r_I/(D \times r_B) + r_A] \times 100$ to: Result = $\{r_I/[(D \times r_B) + r_A]\} \times 100$
LACTATED	*Definition*	*USP36–NF31*	5055	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second*	Line 13:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
RINGER'S INJECTION							*Supplement to USP37–NF32*	Change 408.0 mg of chloride to: 428.0 mg of chloride
BUFFER SOLUTIONS	*4. Standard Buffer Solutions/4.1 Preparation*	*Second Supplement to USP36–NF31*	6244	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of 4. *Boric Acid and Potassium Chloride 0.2 M*: Change 12.73 g/L of boric acid to: 12.37 g/L of boric acid
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 5*	*Second Supplement to USP36–NF31*	6592	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Acid stage sample solution*: Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size. AND Line 3 of *Buffer stage sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size.
ALMOND OIL	SPECIFIC TESTS/*Sterol Composition*	*USP36–NF31*	1877	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Row 9 of *Table 2*: Change ?7-Stigmastenol ?3.0% to: ?7-Stigmastenol ?3.0%
FLUOCINONIDE TOPICAL SOLUTION	*Alcohol content*	*USP36–NF31*	3618	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Standard solution*: Change Dilute 20.0 mL of USP Alcohol to: Dilute 20.0 mL of alcohol
MINERAL OIL	SPECIFIC TESTS	*USP36–NF31*	4372	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Viscosity—Capillary Viscometer Methods <911>*: Change 34.5 and 150.0 $mm^2 \cdot s^{?1}$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 34.5–150.0 $mm^2 \cdot s^{?1}$
ATROPINE SULFATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation* <781>	*First Supplement to USP36–NF31*	5948	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Sample solution*: Change 0.1 mg/mL in water to: 0.1 g/mL of Atropine Sulfate in water
CAPSICUM OLEORESIN	SPECIFIC TESTS/*Limit of Nonivamide*	*Second Supplement to USP36–NF31*	6577	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change on the dried basis to: on the anhydrous basis
RISPERIDONE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP36–NF31*	6690	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a 98.9: 0.5: 0.30: 0.3 (area %)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mixture of four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one]. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-az

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								oniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z-Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl) (hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: Contains a mixture of the following four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one-*N*-oxide. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z*-*Oxime*: (*Z*)-3-[2-[4-(2,4-Difluorophenyl) (hydroxyimino)methyl]-1-piperidiny

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								l]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
BOSWELLIA SERRATA	COMPOSITION */Content of Keto-Derivatives of ?-Boswellic Acids/System suitability/Suitability requirements*	*USP36–NF31*	1366	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Tailing factor*: Change 11-keto-?-boswellic acid peak to: 3-acetyl-11-keto-?-boswellic acid peak
APROTININ	*Limit of des-Ala-aprotinin and des-Ala-des-Gly-aprotinin*	*USP36–NF31*	2522	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Change the subsection head *Capillary zone electrophoresis system* (see *Capillary Electrophoresis* under *Biotechnology-Derived Articles—Test* <1047>)— to: *Capillary zone*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								electrophoresis system—
KETOROLAC TROMETHAMINE TABLETS	IMPURITIES/*Organic Impurities*	*USP36–NF31*	4042	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Sample solution*: Change Proceed as directed for the *Sample stock solution* in the *Assay*. to: Proceed as directed for the *Sample solution* in the *Assay*.
RISPERIDONE	*USP Reference standards <11>*	*USP36–NF31*	5063	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 7 of USP Risperidone System Suitability Mixture RS: Change 9-Hydroxyrisperidone-(6*RS*)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl]-2,6-dimethyl-6,7,8,9-tet

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: 9-Hydroxyrisperidone: (9*RS*)-3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one.
CHINESE SALVIA	COMPOSITION */Content of Salvianolic Acid B*	*Second Supplement to USP36–NF31*	6331	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 16 of *Analysis*: Change *W* = weight of Chinese Salvia used to prepare the *Sample solution* (mg) to: *W* = weight of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chinese Salvia used to prepare the *Sample stock solution* (mg)
LORATADINE	IM PUR ITIES/*Organic Impurities, Procedure 1*	*Second Supplement to USP36–NF31*	6650	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of Note: Change 4,8-dichloro-6,11-dihydro-5*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridin-11-one to: 4,8-dichloro-5,6-dihydro-11*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridin-11-one
POLYETHYLENE GLYCOL MONOMETHYL ETHER	IM PURITIES/*Limit of 2-Methoxyethanol*	*USP36–NF31*	2142	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 11 of *Calibration*: Change On the two *Calibration* plots, to: On the *Calibration* plot,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GADOTERIDOL INJECTION	*Bacterial endotoxins <85>*	*USP36–NF31*	3701	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2: Change gadoteridol. to: Gadoteridol Injection.
OCTINOXATE	*Assay*	*USP36–NF31*	4556	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Chromatographic system*: Change a 0.32-mm × 25-m column that contains coating G1, to: a 0.32-mm × 25-m column with 0.25-µm thickness of phase G1 coating,

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34

- Page 35
- Page 36
- Page 37
- Page 38
- …
- Next page Next ›
- Last page Last »